{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-076938","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.710921+00:00","generated_at":"2026-05-23T18:17:24.230049+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"confidence":"high","headline":"Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee","bullets":["Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.","Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.","Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.","TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.","Company cites unavailable capital markets as reason to seek a strategic partner."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-076938","json":"https://secwatch.observer/filing/0001193125-25-076938.json","markdown":"https://secwatch.observer/filing/0001193125-25-076938.md","text":"https://secwatch.observer/filing/0001193125-25-076938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/0001193125-25-076938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/d906762d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:17:24.230049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}